Atyr PHARMA INC (NASDAQ:ATYR - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Atyr PHARMA in a report released on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal anticipates that the company will post earnings per share of ($0.78) for the year. The consensus estimate for Atyr PHARMA's current full-year earnings is ($0.91) per share.
A number of other equities research analysts have also recently commented on ATYR. Leerink Partners initiated coverage on Atyr PHARMA in a research report on Tuesday, February 18th. They set an "outperform" rating and a $16.00 target price on the stock. Leerink Partnrs raised shares of Atyr PHARMA to a "strong-buy" rating in a research note on Tuesday, February 18th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $35.00 price target on shares of Atyr PHARMA in a research note on Wednesday, June 4th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Atyr PHARMA has a consensus rating of "Buy" and a consensus target price of $18.60.
Get Our Latest Stock Report on Atyr PHARMA
Atyr PHARMA Price Performance
Shares of NASDAQ:ATYR traded down $0.23 during trading on Wednesday, reaching $5.20. 2,111,505 shares of the company's stock traded hands, compared to its average volume of 1,047,299. Atyr PHARMA has a fifty-two week low of $1.42 and a fifty-two week high of $5.98. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02. The firm has a market cap of $462.82 million, a PE ratio of -5.53 and a beta of 0.88. The company has a 50-day simple moving average of $3.75 and a 200-day simple moving average of $3.60.
Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.02.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of ATYR. Federated Hermes Inc. purchased a new position in Atyr PHARMA in the 4th quarter worth approximately $53,093,000. Point72 Asset Management L.P. purchased a new position in Atyr PHARMA in the 4th quarter worth approximately $17,677,000. Octagon Capital Advisors LP lifted its stake in Atyr PHARMA by 294.7% in the 1st quarter. Octagon Capital Advisors LP now owns 3,552,000 shares of the company's stock worth $10,727,000 after purchasing an additional 2,652,000 shares in the last quarter. Tikvah Management LLC purchased a new position in Atyr PHARMA in the 4th quarter worth approximately $8,908,000. Finally, Woodline Partners LP purchased a new position in Atyr PHARMA in the 4th quarter worth approximately $6,092,000. 61.72% of the stock is owned by hedge funds and other institutional investors.
About Atyr PHARMA
(
Get Free Report)
aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Further Reading
Before you consider aTyr Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and aTyr Pharma wasn't on the list.
While aTyr Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
